Literature DB >> 9135048

Effects of alpha-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid.

N Nakao1, P Brundin.   

Abstract

We have investigated the neuroprotective effects of the the spin-trapping agent alpha-phenyl-tert-butyl nitrone on striatal lesions produced by local injections of the excitotoxin quinolinate or the mitochondrial toxin 3-nitropropionic acid. We have assessed both the behavioural and morphological consequences of the lesion. Thus, we tested paw-reaching ability and amphetamine- and apomorphine-induced rotational behaviour in lesioned rats with or without alpha-phenyl-tert-butyl nitrone treatment, and also explored the relationship between the outcome of the behavioural studies and the extent of the lesion. In the morphological analysis, we chose immunocytochemistry for dopamine- and cyclic AMP-regulated phosphoprotein with a molecular weight of 32,000 as a specific marker for striatal neurons. The paw-reaching ability of rats with the quinolinate and 3-nitropropionic acid lesions was significantly impaired compared to normal control animals. Treatment with alpha-phenyl-tert-butyl nitrone significantly ameliorated the paw-reaching deficits produced by the quinolinate lesion, whereas the 3-nitropropionic acid-induced deficits were unaffected by alpha-phenyl-tert-butyl nitrone. Both quinolinate and 3-nitropropionic acid lesions resulted in a rotation asymmetry towards the lesioned side in response to both amphetamine and apomorphine. In the quinolinate lesion model, the alpha-phenyl-tert-butyl nitrone treatment resulted in a less marked motor asymmetry in response to both drugs. By contrast, alpha-phenyl-tert-butyl nitrone did not significantly reduce the drug-induced rotation asymmetry in rats with a 3-nitropropionic acid lesion. Morphological analyses disclosed that alpha-phenyl-tert-butyl nitrone significantly increased the size of the spared striatum in the quinolinate lesions, but only caused a non-significant trend towards an attenuation of the 3-nitropropionic acid lesions. The behavioural deficits were inversely correlated to the size of the spared residual striatum. The intrastriatal injection of 3-nitropropionic acid, unlike the injection of quinolinate, caused degeneration of the nigrostriatal dopamine system as well as of transverse fibre bundles of the internal capsule in the striatum, in addition to the striatal lesion. The behavioural studies revealed that the combination of multiple lesions seen in 3-nitropropionic acid-lesioned rats significantly exacerbated paw-reaching deficits and amphetamine-induced rotation asymmetry. In conclusion, alpha-phenyl-tert-butyl nitrone attenuated behavioural and morphological consequences of striatal lesions induced by local injections of quinolinate, but not of 3-nitropropionic acid. Deficits in behavioural tests of striatal function reflected well the extent of striatal lesion. The intrastriatal injection of 3-nitropropionic acid led to degeneration of both intrinsic striatal neurons and the nigrostriatal dopaminergic system, suggesting that this lesion may provide an animal model of a form of multiple system atrophy rather than Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9135048     DOI: 10.1016/s0306-4522(96)00223-0

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  11 in total

Review 1.  Epidemiological evidence on multiple system atrophy.

Authors:  N Vanacore
Journal:  J Neural Transm (Vienna)       Date:  2005-12       Impact factor: 3.575

2.  Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl.

Authors:  W M Behan; M McDonald; L G Darlington; T W Stone
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

3.  Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice.

Authors:  Wenzhen Duan; Zhihong Guo; Haiyang Jiang; Melvin Ware; Xiao-Jiang Li; Mark P Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-14       Impact factor: 11.205

Review 4.  Tryptophan, adenosine, neurodegeneration and neuroprotection.

Authors:  T W Stone; C M Forrest; G M Mackay; N Stoy; L G Darlington
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

5.  Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease.

Authors:  D S Reynolds; R J Carter; A J Morton
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

6.  Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder.

Authors:  Nicholas W S Davies; Gilles Guillemin; Bruce J Brew
Journal:  Int J Tryptophan Res       Date:  2010-06-10

Review 7.  Kynurenines, neurodegeneration and Alzheimer's disease.

Authors:  Zsigmond Tamas Kincses; József Toldi; László Vécsei
Journal:  J Cell Mol Med       Date:  2010-07-12       Impact factor: 5.310

8.  Targeted deletion of the aquaglyceroporin AQP9 is protective in a mouse model of Parkinson's disease.

Authors:  Katja Stahl; Soulmaz Rahmani; Agnete Prydz; Nadia Skauli; Nanna MacAulay; Maria N Mylonakou; Reidun Torp; Øivind Skare; Torill Berg; Trygve B Leergaard; Ragnhild E Paulsen; Ole P Ottersen; Mahmood Amiry-Moghaddam
Journal:  PLoS One       Date:  2018-03-22       Impact factor: 3.240

9.  Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease.

Authors:  Bronwen Martin; Erin Golden; Olga D Carlson; Paul Pistell; Jie Zhou; Wook Kim; Brittany P Frank; Sam Thomas; Wayne A Chadwick; Nigel H Greig; Gillian P Bates; Kirupa Sathasivam; Michel Bernier; Stuart Maudsley; Mark P Mattson; Josephine M Egan
Journal:  Diabetes       Date:  2008-11-04       Impact factor: 9.461

Review 10.  Quinolinic acid: an endogenous neurotoxin with multiple targets.

Authors:  Rafael Lugo-Huitrón; Perla Ugalde Muñiz; Benjamin Pineda; José Pedraza-Chaverrí; Camilo Ríos; Verónica Pérez-de la Cruz
Journal:  Oxid Med Cell Longev       Date:  2013-09-05       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.